Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT)

International Journal of Radiation Oncology, Biology, Physics
Chia-Lin TsengArjun Sahgal

Abstract

We report mature outcomes for a cohort of patients with no prior radiation (de novo) to the spine treated with 24 Gy in 2 daily fractions for metastases, which represents the same stereotactic body radiation therapy (SBRT) regimen under evaluation in the current Symptom Control-24 phase 3 randomized trial (NCT02512965). The cohort consisted of 279 de novo spinal metastases in 145 consecutive patients treated with 24 Gy in 2 SBRT fractions, identified from a prospective single-institution database. The endpoints were overall survival (OS), imaging-based local failure (LF), and cumulative risk of vertebral compression fractures (VCF). The median follow-up per treated metastasis was 15.0 months (range, 0.1-71.6). The 1-year and 2-year OS rates were 73.1% and 60.7%, respectively. Presence of epidural disease (P < .0001), lung (P = .0415), and renal cell (P < .0001) primary histologies and baseline diffuse metastases (P = .0034) were significant prognostic factors for OS. The 1-year and 2-year LF rates were 9.7% and 17.6%, respectively, and the median time to LF was 9.2 month (range, 0.4-31.3 months). Only the presence of epidural disease predicted for LF (P < .0001). The cumulative risk of VCF at 1 and 2 years was 8.5% and 13.8%, r...Continue Reading

Citations

Jan 3, 2020·JAMA Oncology·Rachel M GlicksmanFabio Y Moraes
May 24, 2019·Frontiers in Oncology·Kang Liang ZengSten Myrehaug
Mar 17, 2020·Journal of Medical Imaging and Radiation Oncology·Hussein AbbouchieFarshad Foroudi
Jun 13, 2020·Frontiers in Oncology·Hongqing ZhuangJiandong Liu
Jan 8, 2021·International Journal of Radiation Oncology, Biology, Physics·Matthias GuckenbergerMichael Flentje
Feb 1, 2021·International Journal of Radiation Oncology, Biology, Physics·Scott G SoltysStanley Benedict
Jun 17, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Xuguang ChenKristin J Redmond
Jun 3, 2021·The Oncologist·Satoshi KatoHiroyuki Tsuchiya
Mar 15, 2020·Clinical Oncology : a Journal of the Royal College of Radiologists·H AbbouchieF Foroudi
Sep 5, 2021·Practical Radiation Oncology·Caleb Dulaney, Laura Dover
Oct 9, 2021·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Sujana GottumukkalaKaruna M Raj
Jul 25, 2020·Journal of Neurosurgery. Spine·Robert J RothrockDaniel S Higginson

❮ Previous
Next ❯

Related Concepts

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.